Keywords
Mineralocorticoids
Heart Failure
Renal Insufficiency
Spironolactone
Eplerenone
Finerenone
How to Cite
Abstract
Background: The role of aldosterone and its receptor is the subject of continuous research and learning, due to its impact on pathological conditions, especially cardiac and renal conditions.
Purpose: Realize a narrative review about the renal and cardiac effect of aldosterone together with its receptor and describe the available evidence in clinical studies of drugs that have aldosterone and it´s receptor as a therapeutic target.
Methodology: In order to answer the question what are the cardiac and renal effects of aldosterone receptor activation in pathological conditions? In addition to, what implemented therapeutic strategies in randomized studies have used? A search we made in the Pubmed database with the keywords and the related Mesh terms.
Results: This review presents a wide variety of alternative action mechanisms of aldosterone and mineralocorticoid receptor and their relationship with other receptors, marking their genomic and non-genomic action, which ultimately lead to promoting inflammation and fibrosis at the cardiac level and renal. Finally, a summary of the phase II and phase III studies of aldosterone antagonists was included and discussed.
Conclusions: Aldosterone is a hormone of great relevance for its action on kidney and heart since its development, the mineralocorticoid receptor revealed as a therapeutic target in which improved drugs stand out for being more specific and for having fewer adverse effects.
References
Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021;143(6):540-52. https://doi.org/10.1161/CIRCULATIONAHA.120.051898
Bollag W. Regulation of Aldosterone Synthesis and Secretion. Compr Physiol. 2014;4. https://doi.org/10.1002/cphy.c130037
Ruhs S, Nolze A, Hübschmann R, Grossman C. Nongenomic effects via the mineralocorticoid receptor. J Endocrinol. 2017;234:T107-24. https://doi.org/10.1530/JOE-16-0659
Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022;18(1):56-70. https://doi.org/10.1038/s41581-021-00490-8
Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system and hypertension. Am J Hypertens. 2021;34(1):15-27. https://doi.org/10.1093/ajh/hpaa137
Erraez S, López-Mesa M, Gómez-Fernández P. Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica. Nefrología. 2021;41(3):258-75. https://doi.org/10.1016/j.nefro.2020.10.001
Richardson RV, Batchen EJ, Denvir MA, Gray GA, Chapman KE. Cardiac GR and MR: From Development to Pathology. Trends Endocrinol Metab. 2016;27(1):35-43. https://doi.org/10.1016/j.tem.2015.10.001
Deo R, Yang W, Khan AM, Bansal N, Zhang X, Leonard MB, et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension. 2014;64(1):103-10. https://doi.org/10.1161/HYPERTENSIONAHA.114.03311
Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022;43(38):3781-91. https://doi.org/10.1093/eurheartj/ehac352
Nagase M, Ayuzawa N, Kawarazaki W, Ishizawa K, Ueda K, Yoshida S, et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomy-ocytes: Role of small GTPase Rac1. Hypertension. 2012;59:5006. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.185520
Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease. Nat Med. 2008;14:1370-6, http://dx.doi.org/10.1038/nm.1879
Verdugo F, Montellano F, Carreño J, Marusic E. Aplicaciones y proyecciones de los antagonistas del receptor de mineralocorticoides en el tratamiento de patologías cardiovasculares. Rev Med Chile. 2014;142:61-71. https://doi.org/10.4067/S0034-98872014000100010
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84. https://doi.org/10.1093/eurheartj/ehab777
Veneti S, Tziomalos K. The Role of Finerenone in the Management of Diabetic Nephropathy. Diabetes Ther. 2021;12(7):1791-7. https://doi.org/10.1007/s13300-021-01085-z
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. https://doi.org/10.1056/NEJM199909023411001
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. https://doi.org/10.1056/NEJMoa030207
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. https://doi.org/10.1056/NEJMoa1009492
Butler J, Anstrom K, Felker M, Givertz M, Kalogeropoulos A, Konstam M, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. 2017;2(9):950-8. https://doi.org/10.1001/jamacardio.2017.2198
Fu Y, Hall JE, Lu D, Lin L, Manning RD Jr, Cheng L, et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension. 2012;59:599-606. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.173195
Wang H, d’Ambrosio MA, Garvin JL, Ren Y, Carretero OA. Connecting tubule glomerular feedback in hypertension. Hypertension. 2013;62:738-45. http://dx.doi.org/10.1161/HYPERTENSIONA HA.113.01846
Wang H, d’Ambrosio MA, Ren Y, Monu SR, Leung P, Kutskill K, et al. Tubuloglomerular and connecting tubuloglomerular feedback during inhibition of various Na transporters in the nephron. Am J Physiol Renal Physiol. 2015;308:F1026-31. https://doi.org/10.1152/ajprenal.00605.2014
Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528-36. http://dx.doi.org/10.1016/j.jacc.2013.09.056
Quach K, Lvtvyn L, Baigent C, Bueti J, Garg AX, Hawley C, et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: A systematic review and meta-analysis. Am J Kidney Dis. 2016;68:591-8. http://dx.doi.org/10.1053/j.ajkd.2016.04.011
Li Y, Xie N, Liang M. Aldosterone antagonists reduce the risk of cardiovascular mortality in dialysis patients: A meta-analysis. Evid Based Complement Alternat Med. 2019:1925243. http://dx.doi.org/10.1155/2019/1925243
Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365-76. https://doi.org/10.1111/dom.14601
Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Kim SY, et al. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J. 2016;80(5):1113-22. https://doi.org/10.1253/circj.CJ-16-0122
Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-63. https://doi.org/10.1093/eurheartj/eht187
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884-94. https://doi.org/10.1001/jama.2015.10081
Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31(4):758-65. https://doi.org/10.1016/j.jdiacomp.2016.11.021
Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14. https://doi.org/10.1093/eurheartj/ehw132
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29. https://doi.org/10.1056/NEJMoa2025845
Pitt B, Filippatos G, Agarwal R, Anker S, Bakris G, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes; N Engl J Med. 2021;385:2252-63. https://doi.org/10.1056/NEJMoa2110956
American Diabetes Association. Standards of Medical Care in Diabetes 2022. 2022;45(supl. 1):S1-2. https://doi.org/10.2337/dc22-Sint
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo